Open an account

VolitionRX

VNRX · NYSE American

$0.1732−$0.0006 (−0.35%)TodayMarket closed ·
Prev close $0.1738

About VNRX

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 75 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Employees
75
Headquarters
Henderson, Nevada
Listed
Feb 6, 2015
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
volition.com

VNRX key statistics

Market cap
5.03M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.72M
Volume
593.17K
Open price
$0.1699
High today
$0.1788
Low today
$0.1627
52 Week high
$9.60
52 Week low
$0.1676

VolitionRX (VNRX) at a glance

As of Oct 20, 2026, VolitionRX (VNRX) shares are priced at $0.1732, giving the company a market cap of 5.03M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.1627 and $0.1788. The current price is 6.5% above the day's low and 3.1% below its high.

Volume so far is 593.17K shares, below the average of 1.72M shares a day.

Over the past year VolitionRX has ranged from $0.1676 to $9.60, and now sits 0% of the way up that range.

VolitionRX met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.85 per share against an estimate of -$0.5855.

The average analyst price target is $13.89, 7922.2% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 4 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 7 analystsAvg $13.89
Low
$2.02
Now
$0.1732
High
$25.20

VNRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 2.0% on average.

  1. Q3 FY24: reported -$1.40 per share against an estimate of -$1.43
  2. Q4 FY24: reported -$1.20 per share against an estimate of -$1.17
  3. Q1 FY25: reported -$1.20 per share against an estimate of -$0.918
  4. Q2 FY25: reported -$1.20 per share against an estimate of -$1.02
  5. Q3 FY25: reported -$1.00 per share against an estimate of -$0.8976
  6. Q4 FY25: reported -$1.04 per share against an estimate of -$0.8501
  7. Q1 FY26: reported -$0.97 per share against an estimate of -$0.7344
  8. Q2 FY26: reported -$0.85 per share against an estimate of -$0.5855

VNRX news

  • Press releasePRNewswire

    VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

  • Press releasePRNewswire

    VolitionRx Participates in Launch of DETECSEPS Program in France

  • Press releasePRNewswire

    VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

  • Press releasePRNewswire

    Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results

  • Vandana Singh

    Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

  • Press releasePRNewswire

    VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

Similar companies

Companies in the same industry as VolitionRX

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.